2. Academic Validation
  3. CCR7 Mediated Mimetic Dendritic Cell Vaccine Homing in Lymph Node for Head and Neck Squamous Cell Carcinoma Therapy

CCR7 Mediated Mimetic Dendritic Cell Vaccine Homing in Lymph Node for Head and Neck Squamous Cell Carcinoma Therapy

  • Adv Sci (Weinh). 2023 Apr 24;e2207017. doi: 10.1002/advs.202207017.
Jiabin Xu 1 2 3 4 5,  Hong Liu 6,  Tao Wang 1 2 3,  Zhenfu Wen 6,  Haolin Chen 6,  Zeyu Yang 6,  Liyan Li 6,  Shan Yu 1 2 3,  Siyong Gao 1 2 3,  Le Yang 1 2 3,  Kan Li 1 2 3,  Jingyuan Li 1 2 3,  Xiang Li 1 2 3,  Lixin Liu 6,  Guiqing Liao 1 2 3,  Yongming Chen 6,  Yujie Liang 1 2 3
Affiliations

Affiliations

  • 1 Hospital of Stomatology, Sun Yat-sen University, Guangzhou, 510030, P. R. China.
  • 2 Guangdong Provincial Key Laboratory of Stomatology, Guangzhou, 510030, P. R. China.
  • 3 Institute of Stomatology, Sun Yat-sen University, Guangzhou, 510030, P. R. China.
  • 4 School of Stomatology, Xuzhou Medical University, Xuzhou, 221004, P. R. China.
  • 5 Affiliated Stomatological Hospital of Xuzhou Medical University, Xuzhou, 221004, P. R. China.
  • 6 School of Materials Science and Engineering, Key Laboratory for Polymeric Composite and Functional Materials of Ministry of Education, Sun Yat-sen University, Guangzhou, 510275, P. R. China.
PMID: 37092579 DOI: 10.1002/advs.202207017
Abstract

Immunotherapy has been recognized as one of the most promising treatment strategies for head and neck squamous cell carcinoma (HNSCC). As a pioneering trend of immunotherapy, dendritic cell (DC) vaccines have displayed the ability to prime an immune response, while the insufficient immunogenicity and low lymph node (LN) targeting efficiency, resulted in an unsubstantiated therapeutic efficacy in clinical trials. Herein, a hybrid nanovaccine (Hy-M-Exo) is developed via fusing tumor-derived exosome (TEX) and dendritic cell membrane vesicle (DCMV). The hybrid nanovaccine inherited the key protein for lymphatic homing, CCR7, from DCMV and demonstrated an enhanced efficiency of LN targeting. Meanwhile, the reserved tumor antigens and endogenous danger signals in the hybrid nanovaccine activated antigen presenting cells (APCs) elicited a robust T-cell response. Moreover, the nanovaccine Hy-M-Exo displayed good therapeutic efficacy in a mouse model of HNSCC. These results indicated that Hy-M-Exo is of high clinical value to serve as a feasible strategy for antitumor immunotherapy.

Keywords

CCR7; head and neck squamous cell carcinoma; lymph node targeting; nanovaccines; tumor-derived exosomes.

Figures
Products